ERBB2 and breast carcinoma: While TRAF4 was overexpressed in almost all subtypes of breast cancer, the overexpression was more prominent in HER2+/HR− breast cancer samples compared to HER2−/HR+ and TN breast cancer samples (Fig. 1A).